IOVANCE BIOTHERAPEUTICS, INC. reported second-quarter 2026 results with revenue of $99.3M, a narrowed net loss of $47.3M versus a $111.7M loss in the prior-year quarter, and diluted EPS of $(0.11), reflecting improved performance driven by commercial growth.
Financial Highlights
- Revenue was $99.3M for 2Q 2026, compared with $59.95M in 2Q 2025; YoY change 66%.
- Net income was a loss of $47.3M for 2Q 2026, compared with a loss of $111.7M in 2Q 2025; loss narrowed by $64.3M YoY.
- Diluted EPS was $(0.11) for 2Q 2026, compared with $(0.33) for 2Q 2025; improvement of $0.22 YoY.
Business Highlights
- Product revenue growth of 66% year-over-year was driven by increased Amtagvi® infusions and higher Proleukin® sales and pricing.
- All tumor-infiltrating lymphocyte (TIL) manufacturing has transitioned in-house to the iCTC to scale capacity, reduce reliance on CMOs and lower long-term costs.
- Amtagvi® is approved in the U.S., Canada and Australia, with regulatory submissions ongoing in the U.K., EU and Switzerland to support additional launches and market access.
- iCTC manufacturing capacity is designed to support more than 5,000 patients per year; commercial scale-up efforts include ATC onboarding and expanded patient-support and training programs.
- R&D spend has declined as late-stage trials completed; registrational trials continue in frontline melanoma, NSCLC and sarcoma.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.